Dermira, Inc. (NASDAQ:DERM) Weekly Ratings on May 17, 2018

May 17, 2018 - By Cynthia Ashman

Dermira, Inc. (NASDAQ:DERM) Corporate Logo
During 2017 Q4 the big money sentiment decreased to 1.27. That’s change of 0.76, from 2017Q3’s 2.03. 16 investors sold all, 35 reduced holdings as Dermira, Inc. ratio turned negative. 40 grew positions while 25 funds bought positions. Funds hold 38.81 million shares thus 5.56% less from 2017Q3’s 41.09 million shares.
Metropolitan Life Ins Com Ny stated it has 0% of its capital in Dermira, Inc. (NASDAQ:DERM). D E Shaw Incorporated reported 0% of its capital in Dermira, Inc. (NASDAQ:DERM). California-based California State Teachers Retirement Systems has invested 0% in Dermira, Inc. (NASDAQ:DERM). Eventide Asset Limited Liability owns 0.18% invested in Dermira, Inc. (NASDAQ:DERM) for 124,000 shs. Price T Rowe Inc Md reported 2.53 million shs stake. Susquehanna Int Group Llp reported 64,214 shs stake. Balyasny Asset Ltd Liability Co reported 963,414 shs stake. Moreover, Envestnet Asset Mgmt Inc has 0% invested in Dermira, Inc. (NASDAQ:DERM). 95,000 were accumulated by Rhenman & Prtn Asset Management Ab. Franklin Resources has invested 0.01% of its capital in Dermira, Inc. (NASDAQ:DERM). Dekabank Deutsche Girozentrale has invested 0% of its capital in Dermira, Inc. (NASDAQ:DERM). 100,000 were accumulated by Ghost Tree Capital Ltd Com. Nea Limited Company reported 3.51M shs. Private Cap Advsr holds 0.34% or 35,000 shs. Parallax Volatility Advisers Limited Partnership stated it has 25,947 shs.

Dermira, Inc. registered $1.01 million net activity with 0 insider buys and 10 insider sales since December 13, 2017. On Monday, December 18 the insider BAUER EUGENE A sold $82,011. On Tuesday, January 2 Shares for $499,354 were sold by Griffith Christopher M.. WIGGANS THOMAS G sold $137,566 worth of Dermira, Inc. (NASDAQ:DERM) on Wednesday, December 13.

Dermira, Inc. (NASDAQ:DERM) Ratings Coverage

Total analysts of 5 have positions in Dermira (NASDAQ:DERM) as follows: 3 rated it a “Buy”, 0 with “Sell” and 2 with “Hold”. The positive are 60%. Since December 5, 2017 according to StockzIntelligence Inc Dermira has 9 analyst reports. On Tuesday, March 6 the rating was downgraded by Guggenheim to “Neutral”. On Monday, March 5 Mizuho downgraded the shares of DERM in report to “Hold” rating. On Friday, February 23 Mizuho maintained Dermira, Inc. (NASDAQ:DERM) rating. Mizuho has “Buy” rating and $39.0 target. On Thursday, May 3 the firm has “Buy” rating by Cantor Fitzgerald given. On Tuesday, December 5 the firm earned “Buy” rating by Guggenheim. On Tuesday, December 12 the firm has “Buy” rating given by Mizuho. The stock rating was maintained by Cantor Fitzgerald with “Buy” on Thursday, February 22. On Wednesday, January 17 the rating was maintained by Leerink Swann with “Buy”. Listed here are Dermira, Inc. (NASDAQ:DERM) PTs and latest ratings.

03/05/2018 Broker: Cantor Fitzgerald Rating: Buy New Target: $20.0000 Maintain
06/03/2018 Broker: Guggenheim Old Rating: Buy New Rating: Neutral Downgrade
05/03/2018 Broker: Mizuho Rating: Hold Downgrade
05/03/2018 Broker: Cowen & Co Rating: Buy New Target: $25.0
23/02/2018 Broker: Mizuho Rating: Buy New Target: $39.0 Maintain
22/02/2018 Broker: Cantor Fitzgerald Rating: Buy New Target: $45.0 Maintain
17/01/2018 Broker: Leerink Swann Rating: Buy New Target: $48.0 Maintain
12/12/2017 Broker: Mizuho Rating: Buy New Target: $39.0 Maintain
05/12/2017 Broker: Guggenheim Rating: Buy Initiate

The stock increased 3.53% or $0.38 during the last trading session, reaching $11.13.Dermira, Inc. has volume of 165,295 shares. Since May 17, 2017 DERM has declined 77.97% and is downtrending. DERM underperformed the S&P 500 by 89.52%.

Dermira, Inc., a biopharmaceutical company, engages in identifying, developing, and commercializing therapies to enhance the lives of patients with dermatologic diseases primarily in the United States.The firm is valued at $465.77 million. The companyÂ’s late-stage product candidates include Cimzia, an injectable biologic tumor necrosis factor-alpha inhibitor to treat various inflammatory diseases, as well as to treat patients with moderate-to-severe chronic plaque psoriasis; Glycopyrronium tosylate, a small-molecule anticholinergic product that is in Phase III clinical trial for the treatment of primary axillary hyperhidrosis or excessive underarm sweating; and Olumacostat glasaretil, a small-molecule sebum inhibitor, which is in Phase III clinical trial to treat acne vulgaris or acne.Currently it has negative earnings. It has a collaboration agreement with UCB Pharma S.A. for the development and commercialization of Cimzia.

For more Dermira, Inc. (NASDAQ:DERM) news published briefly go to: Nasdaq.com, Globenewswire.com, Globenewswire.com, Globenewswire.com or Globenewswire.com. The titles are as follows: “Dermira and Cameran Eubanks Team Up to Raise Awareness of Excessive Sweating for the 15 Million People Living …” published on May 02, 2018, “Dermira Reports First Quarter 2018 Financial Results and Provides Corporate Update” on May 03, 2018, “Dermira to Present at Deutsche Bank 43rd Annual Healthcare Conference” with a publish date: May 01, 2018, “Christopher Horan Joins Dermira as Chief Technical Operations Officer” and the last “Dermira to Host Analyst & Investor Day on May 24, 2018” with publication date: May 14, 2018.

Dermira, Inc. (NASDAQ:DERM) Institutional Investors Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.